Can-Fite BioPharma Ltd.
CANF · AMEX
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $101 | $101 | $179 | $179 |
| % Growth | 0% | -43.6% | 0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $101 | $101 | $179 | $179 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $1,517 | $1,517 | $1,436 | $1,436 |
| G&A Expenses | $1,033 | $1,033 | $761 | $761 |
| SG&A Expenses | $1,033 | $1,033 | $761 | $761 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,550 | $2,550 | $2,197 | $2,197 |
| Operating Income | -$2,449 | -$2,449 | -$2,018 | -$2,018 |
| % Margin | -2,424.8% | -2,424.8% | -1,127.4% | -1,127.4% |
| Other Income/Exp. Net | $11 | $11 | $56 | $56 |
| Pre-Tax Income | -$2,438 | -$2,438 | -$1,961 | -$1,961 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,438 | -$2,438 | -$1,961 | -$1,961 |
| % Margin | -2,413.9% | -2,413.9% | -1,095.5% | -1,095.5% |
| EPS | -0.21 | -0.21 | -0.24 | -0.24 |
| % Growth | 0% | 12.5% | 0% | – |
| EPS Diluted | -0.21 | -0.21 | -0.24 | -0.24 |
| Weighted Avg Shares Out | 11,382 | 11,382 | 8,437 | 8,437 |
| Weighted Avg Shares Out Dil | 11,373 | 11,373 | 8,435 | 8,435 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $11 | $77 | $77 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $12 | $12 | $3 | $3 |
| EBITDA | -$2,438 | -$2,438 | -$2,015 | -$2,015 |
| % Margin | -2,413.4% | -2,413.4% | -1,125.7% | -1,125.7% |